GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » 3-Year EPS without NRI Growth Rate

Diamyd Medical AB (FRA:DMN) 3-Year EPS without NRI Growth Rate : -8.20% (As of Feb. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB 3-Year EPS without NRI Growth Rate?

Diamyd Medical AB's EPS without NRI for the three months ended in Feb. 2025 was €-0.04.

During the past 3 years, the average EPS without NRI Growth Rate was -8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Diamyd Medical AB was 24.10% per year. The lowest was -340.10% per year. And the median was -8.20% per year.


Competitive Comparison of Diamyd Medical AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Diamyd Medical AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's 3-Year EPS without NRI Growth Rate falls into.


;
;

Diamyd Medical AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Diamyd Medical AB  (FRA:DMN) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Diamyd Medical AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.